Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer
(MedPage Today) -- SAN DIEGO -- Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) who received atezolizumab (Tecentriq) after undergoing multimodal definitive therapy failed to achieve a statistically meaningful...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Hematology | Immunotherapy | Skin Cancer | Squamous Cell Carcinoma | Statistics